GlassScriptPhysician profile
Brian H Negus
NPI 1689673998
$5,126.33
in general payments reported to CMS, 2019-2025
25 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $492 · 2021: $349 · 2022: $1,139 · 2023: $814 · 2024: $512 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,227.85 | 2021-2025 | Symplicity G3, Onyx Frontier, Acist Rxi System |
| Edwards Lifesciences Corporation | $1,225.29 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbott Laboratories | $586.15 | 2019-2025 | Mitraclip, Xience Skypoint, Gallant |
| Medtronic Vascular, INC. | $373.09 | 2019-2020 | |
| Abiomed | $247.05 | 2019-2025 | Impella |
| Boston Scientific Corporation | $227.60 | 2019-2025 | General - Therapies, Watchman Flx, General - Atherectomy |
| Heartflow, INC. | $194.39 | 2025 | |
| Shockwave Medical, INC | $183.28 | 2021-2022 | |
| Atricure, INC. | $163.27 | 2022 | |
| Getinge USA Sales, LLC | $119.49 | 2023 | Cardiohelp |
| Novartis Pharmaceuticals Corporation | $107.16 | 2019-2025 | |
| Pfizer INC. | $106.05 | 2022-2025 | |
| Amgen INC. | $67.47 | 2024-2025 | Repatha, Repatha |
| Asahi Intecc USA, INC. | $58.21 | 2020 | |
| Janssen Pharmaceuticals, INC | $46.86 | 2023-2024 | Xarelto |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $40.59 | 2023 | Ozempic, Rybelsus |
| Biotronik INC. | $30.87 | 2025 | Orsiro Mission |
| Astrazeneca Pharmaceuticals LP | $25.63 | 2020-2022 | |
| Cardiovascular Systems INC. | $18.85 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.33 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.62 | 2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.08 | 2021 | |
| Philips North America LLC | $14.21 | 2024 | (Br3) Coronary Other |
| Biosense Webster, INC. | $12.94 | 2023 | Carto 3 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Negus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.